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Abstract
Purpose The aim of this study was to
determine the prevalence of ocular and
oculodermal melanocytosis (ODM) among
patients with uveal melanoma (UM) in a
Spanish population.
Methods Retrospective review of the medical
records of patients with ODM among patients
with UM.
Results Ten (11 eyes) of 400 patients (2.7%)
with UM associated had ODM. The mean age
at diagnosis of UM among patients with ODM
was 62 years. One patient had bilateral
tumours. UM was diagnosed during a routine-
examination in two cases. All tumours were
medium (7/11) or large (4/11) in size, with a
mean maximum base of 13mm and height of
7mm. No patient had extraocular extension or
metastatic disease at diagnosis. Enucleation
was done in five cases and I-125-brachytherapy
in six. The mean follow-up was 43 months.
One patient died because of metastasis 2 years
after enucleation; one patient is currently on
treatment of systemic metastasis 11 years after.
Conclusions ODM is more frequent in
spanish population with UM than in
American population. Despite the risk of UM
in ODM, it is often diagnosed late when a
conservative treatment is not indicated.
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Introduction
Ocular melanocytosis (OM), a congenital
condition first described by the Japanese
dermatologist Ota in 1939,1 is characterised by
hyperpigmentation of the episclera and uvea2,3
due to an increased number of fusiform dendritic
melanocytes.4 When the disease involves the skin
in the distribution of the ophthalmic branch
of the trigeminal nerve, it is referred to as
oculodermal melanocytosis (ODM) (nevus of
Ota). OM/ODM are more common in Asian
patients,5 but there is a clear association with
the presence of uveal melanoma (UM) in
Caucasians.6–8 Varying involvement of the orbit
and meninges can occur.9
An association between UM and OM/ODM
is supported strongly by previous findings such
as the early onset of UM,10 the ipsilaterality of
the OM/ODM with the UM, and sectorial
OM/ODM progressing to UM in the affected
sector11 as well as cases of bilateral and
multifocal UM.10,12 The association of ODM
with malignant melanomas in the orbit or
intracranially also was reported.13–15 Despite
that, patients with OM/ODM sometimes do not
have adequate follow-up.
The aim of this paper was to determine the
relative incidence of OM/ODM in patients with
UM in Spanish population.
Case reports
Patients from the Intraocular-Tumours-Unit of
‘Hospital Clı´nico Universitario de Valladolid’
from 1992 to 2009 with concurrent UM and
OM/ODM were included. This study was a
case series. Diagnosis of UM was based
on ophthalmoscopic appearance and
ultrasonographic features. Pigmented lesions
41mm in height or base45mm were included
based on the criteria of the Collaborative Ocular
Melanoma Study (COMS).16 The COMS size
classification and the TNM classification
system17 were used.
Received: 6 May 2011
Accepted in revised form:
15 August 2011
Presented in part as an
electronic poster at the 17th
Congress of the European
Society of Ophthalmology,
June 2009, Amsterdam,
The Netherlands.
1Ophthalmology
Department, Hospital
Clinico Universitario,
Valladolid, Spain
2Intraocular Tumors Referral
Unit National Health
System, Hospital Clı´nico
Universitario Valladolid,
Spain
3Radiotherapy Department,
Hospital Clı´nico Universitario
de Valladolid, Spain
4Epidemiology and
Preventive Medicine
Department, Valladolid
University, Spain
Correspondence: E Carren˜o,
Department of
Ophthalmology, Hospital
Clı´nico Universitario,
C/ Ramo´n y Cajal 3,
Valladolid 47005, Spain
Tel: þ34 98 342 0000;
Fax: þ 34 98 325 7511.
E-mail: carregnito@
gmail.com
Eye (2011), 1–4
& 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11
www.nature.com/eye
C
A
S
E
S
E
R
IE
S
Diagnosis of ocular melanocytosis was based on
biomicroscopic and ophthalmoscopic appearance, and
oculodermal melanocytosis was diagnosed in the
presence of dermal involvement.
Demographic information; onset; extent of
melanocytosis, fundus-eye examination, B-mode-
ultrasound with vector-A; measurement of tumour
diameter, height, size, shape, and location were recorded.
Ancillary tests were used to detect extraocular extension
and identify systemic metastasis. Treatment included
enucleation or I-125-brachytherapy. Pathology data were
classified according to the modifications of Callender’s-
classification of UM at the Armed Forces Institute of
Pathology.18 Follow-up examinations were conducted every
6 months during the first 5 years and yearly thereafter.
Data were codified in a database designed in Microsoft
Access. A descriptive analysis was performed.
Eleven eyes (2.7%) (10 patients) of 401 (400 patients) in
the UM database of the Intraocular Tumours Unit, with
data recorded over the course of 17years, had OM/ODM.
Demographic information and clinical features are
recorded in Table 1. All patients presented a tumour
ipsilateral to the eye with OM/ODM. All cases of
OM/ODM showed a diffuse involvement, with affection
of episclera, and uvea, plus skin involvement in the cases
of ODM. No extraocular extension or metastatic disease
was observed at the time of diagnosis of the UM in
any patient.
Three patients underwent enucleation at ‘Hospital
Clı´nico de Valladolid’; one had the mixed-cell melanoma
(case 2), one the spindle-cell melanoma (case 3), and one
the epitheloid-cell melanoma (case 6).
In six cases treated with I-125-brachytherapy, the
mean-dose to apex was 82.25 Gy. No intraocular tumour
recurrence was observed during the follow-up.
One patient died because of metastasis 2 years after
enucleation (case 2), and one patient is receiving systemic
treatment for metastasis 11years after enucleation (case 3).
Discussion
OM/ODM affect only about 0.038% of the general
Caucasian population,19 and, in this series, 2.7% of
patients with UM had OM/ODM, indicating that
OM/ODM is about 71 times more common in the UM
population. Another series reported it to be about 35
times more common in patients with UM.8 Using Bayes’
theorem and previous data, and a prevalence for UM of
7.5 105,20 the lifetime prevalence of UM in patients
with OM/ODM was 5.32 103.
Unfortunately, there are no studies determining the
prevalence of OM/ODM in a Spanish population, and
the prevalence of 0.038% is from a general Caucasian
population in the United States.19
Compared with other series, the current series presents
a higher prevalence of OM/ODM in UM population. The
prevalence reported ranged between 1.24 and 1.36%.6–8
The 2.7% prevalence rate in the current series is
statistically higher than the 1.24%7 rate (P¼ 0.03) and in
the limits of statistical significance compared with the
1.36%6 rate (P¼ 0.057). This disparity could be explained
by differences between populations and environmental
conditions. The decreasing north-to-south gradient of the
incidences of UM in Europe was reported.21 The
differences could result from the different eye colours,21
or exposure to solar radiation.22 It is then possible to
assume that the risk factors for UM, such as OM/ODM,
have different roles depending on the geographic area.
Although OM/ODM is a risk factor for UM, with a
higher prevalence in our population, most patients have
Table 1 Clinical and tumour characteristics
Case
No
Age
(Years)
Gender Eye OM/
ODM
Symptoms
At Onset
Ultrasound Size Localization Shape Treatment Systemic
Metastasis
Follow-Up
(months)
Maximum
base (mm)
Height
(mm)
1 63 M OD OM No 13.00 4.45 Medium Choroid NODULAR BRACHYTHERAPY No 144
2 42 F OS OM Yes 16.10 2.93 Large Choroid INFILTRATIVE ENUCLEATION YES 15
3 31 M OS OM Yes 13.30 5.10 Medium Choroid NODULAR ENUCLEATION YES 90
4 79 M OD OM Yes 20.00 14.80 Large Choroid MUSHROOM ENUCLEATION No F
5 56 M OD OM Yes 9.79 4.58 Medium Choroid NODULAR BRACHYTHERAPY No F
6 84 F OS ODM Yes 18.00 13.00 Large Choroid MUSHROOM ENUCLEATION No 48
7 78 M OS OM No 11.43 7.63 Medium Choroid MUSHROOM BRACHYTHERAPY No 24
8 40 F OS ODM Yes 7.45 8.06 Medium Choroid MUSHROOM BRACHYTHERAPY No 9
9 76 M OD OM Yes 16.80 9.70 Large Ciliary
Body
MUSHROOM ENUCLEATION No F
10 75 M BE OM Yes 10.63 3.74 Medium Choroid NODULAR BRACHYTHERAPY No 13
12.69 8.70 Medium Choroid MUSHROOM BRACHYTHERAPY No 2
Mean 62.40 13.31 7.52 43.13
SD 19.07 3.90 3.86 49.74
Abbreviations: SD, Standard deviation; M, Male; F, Female; OD, Right eye; OS, Left eye; BE, Both eyes; OM, Ocular Melanocytosis; ODM, Oculodermal
melanocytosis.
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not had adequate follow-up; the main reason for the
diagnosis was the development of visual symptoms.
Most UM are diagnosed when they are medium to large
in size, resulting in a high rate of enucleation. When the
tumour is detected early, conservative treatment with
brachytherapy is possible and effective and can preserve
the eye and, in some cases, the visual acuity.
In conclusion, although OM/ODM are important risk-
factors for UM, with a higher prevalence in our
population, most patients do not have adequate follow-
up. Yearly ocular examinations are recommended to
preserve the eye and vision, and improve the prognosis.
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Caucasians. The prevalence reported in patients with
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